DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Authors: Nicole S Kim, Medical Student, University of Toronto, Toronto, Canada; Dr Yuliya Velykoredko, Dermatology Resident, University of Toronto, Toronto, Canada. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell/Maria McGivern. September 2018.
Juvenile idiopathic arthritis (JIA) encompasses all chronic childhood arthropathies beginning before 16 years of age with persistent arthritis occuring for at least 6 weeks.
JIA is recognised as having seven major subtypes, some of which exhibit the clinical and pathological features of other autoimmune disorders; these subtypes include:
Juvenile idiopathic arthritis
JIA can occur in anyone from infants to adolescents, and has a mean onset age of 6 years of age. Most types of JIA affect boys and girls equally, although systemic-onset JIA (juvenile-onset Still disease) is predominantly seen in girls .
The exact cause of JIA is unclear, but a pronounced immune response in a perpetuating loop of both innate and adaptive immunity is believed to contribute to the pathogenesis of JIA. Aberrant activation of the innate immune system lead to the dysregulated production of proinflammatory cytokines. Tumour necrosis factor alpha (TNF-α), interleukin (IL)-1, and IL-6 play a critical inciting role. The effects of these cytokines provide explanations for the various clinical features seen in systemic JIA. These effects include:
The increased recruitment of inflammatory cells in the joint synovial membrane was demonstrated in several studies by a significant elevation of proinflammatory cytokines in the synovial fluid of affected children. Proinflammatory cytokines in the synovium lead to increased production and accumulation of synovial fluid and thickening of the synovial lining. This chronic synovial inflammation is apparent and common to all JIA subtypes. In addition, RANKL (receptor activator of nuclear factor kappa-Β ligand) cytokine, which is associated with bone resorption (breakdown) and cartilage damage, was reported to be present in large amounts in the synovial membrane of children with JIA.
Some studies have consistently supported associations between enthesitis-related JIA and human leukocyte antigen (HLA) polymorphisms; there appear to be increased associations, especially with early-onset disease. A monogenic form of systemic JIA with an underlying mutation in a regulatory protein involved in macrophage metabolism has been described [2,3].
Environmental factors may contribute to the development of JIA. Some studies have suggested associations with exposure to antibiotics, a bacterial infection in immunosuppressed individuals, and maternal smoking during pregnancy [2,4].
Cutaneous involvement is one of the key extra-articular factors in systemic JIA. The exanthem or rash presents as discrete, salmon-pink macules, or oedematous papules that are typically transient and coincide with fevers. These tend to occur on the trunk, axillae, and proximal extremities but are not commonly seen on the palms, soles, or the face. Persistent plaques, periorbital oedema, or erythema are less common but may be observed.
Although rashes in JIA are seldom pruritic, they can be elicited by cutaneous injury or scratching (Koebner phenomenon), in which case the lesions exhibit a linear appearance.
Children with JIA often present with limping and stiffness, without any known injury or prior infections. Common non-cutaneous manifestations include:
Musculoskeletal complications may occur secondary to ongoing inflammation and poor disease control, including:
Sometimes JIA may result in more severe complications with devastating outcomes. These may include:
The diagnosis of systemic JIA is made clinically after exclusion of other entities, such as malignancies and infections that can also present with high fever and arthralgia. According to the International League of Associations for Rheumatology (ILAR) criteria for systemic JIA, arthritis must have persisted for at least 6 weeks and fever for 2 weeks, accompanied by one or more of the following:
When JIA is suspected, paediatric rheumatologists should be involved promptly to initiate the appropriate investigations and to minimise any delay in treatment. Further investigations including laboratory tests and imaging are helpful to confirm the diagnosis or to classify arthritis into a specific subtype. The test results can also be useful to guide treatment and to monitor the disease course.
The most relevant laboratory tests for JIA are:
Pathology is not required for a definitive diagnosis of JIA, but the exanthem in systemic JIA characteristically exhibits a perivascular and interstitial neutrophil-dominant infiltrate; this can also be referred to as neutrophilic urticarial dermatosis, a common pattern in autoinflammatory processes .
Imaging can provide information about the involved joints if the clinical examination findings are equivocal. An ultrasound scan can assess synovitis in the joints, and magnetic resonance imaging may be used to rule out other conditions such as pigmented villonodular synovitis (inflammation of the joint lining) .
Several conditions may present similarly to systemic-onset JIA, including having a transient exanthem, fever, and arthritis. These include:
Treatment of systemic JIA is directed at symptom management, improving or managing joint function, and minimising complications. Non-steroidal anti-inflammatory drugs (NSAIDs) are typically the first-line agents for mild articular or extra-articular presentations to control pain. Other pharmacological agents include:
Drugs that block inflammatory cytokines, such as TNF-α, IL-6, and IL-1, have proven efficacy, especially in longstanding JIA. These include:
The disease course of systemic JIA is variable. Reports have indicated that 40–60% of patients reach the remission of arthralgia. Systemic manifestations may remain active and may persist after years. A better prognosis is associated with the early treatment of active disease [2,3].
© 2021 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.